Recent lipoprotein(a) trials.

IF 3.8 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current opinion in lipidology Pub Date : 2022-12-01 DOI:10.1097/MOL.0000000000000856

Trent Wei, Leslie Cho

{"title":"Recent lipoprotein(a) trials.","authors":"Trent Wei, Leslie Cho","doi":"10.1097/MOL.0000000000000856","DOIUrl":null,"url":null,"abstract":"Purpose of review: Lipoprotein(a) (Lp(a)) is a genetically determined independent risk factor for cardiovascular disease and calcific aortic stenosis; thus, serum levels are minimally affected by conventional treatments for hypercholesterolemia and hypertriglyceridemia. New RNA therapies directly targeting Lp(a) have demonstrated efficacy in decreasing serum levels. Several recent trials have demonstrated efficacy and safety of these RNA therapeutics.Recent findings: Single-stranded antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are two classes of RNA-targeted therapeutics that specifically target the LPA gene, which encodes for apolipoprotein(a), a dominant and rate-limiting component in the hepatic synthesis of Lp(a) particle. Pelacarsen (ASO), olpasiran (siRNA) and SLN360 (siRNA) are novel drugs that have demonstrated efficacy in lowering Lp(a) levels and excellent safety profiles.Summary: Lp(a) is an independent risk factor for cardiovascular disease. RNA-directed therapies, pelacarsen, olpasiran and SLN360, have shown efficacy in dramatically lowering serum Lp(a) levels. Outcomes data will be the next frontier of Lp(a) trials.","PeriodicalId":11109,"journal":{"name":"Current opinion in lipidology","volume":"33 6","pages":"301-308"},"PeriodicalIF":3.8000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOL.0000000000000856","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Purpose of review: Lipoprotein(a) (Lp(a)) is a genetically determined independent risk factor for cardiovascular disease and calcific aortic stenosis; thus, serum levels are minimally affected by conventional treatments for hypercholesterolemia and hypertriglyceridemia. New RNA therapies directly targeting Lp(a) have demonstrated efficacy in decreasing serum levels. Several recent trials have demonstrated efficacy and safety of these RNA therapeutics.

Recent findings: Single-stranded antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) are two classes of RNA-targeted therapeutics that specifically target the LPA gene, which encodes for apolipoprotein(a), a dominant and rate-limiting component in the hepatic synthesis of Lp(a) particle. Pelacarsen (ASO), olpasiran (siRNA) and SLN360 (siRNA) are novel drugs that have demonstrated efficacy in lowering Lp(a) levels and excellent safety profiles.

Summary: Lp(a) is an independent risk factor for cardiovascular disease. RNA-directed therapies, pelacarsen, olpasiran and SLN360, have shown efficacy in dramatically lowering serum Lp(a) levels. Outcomes data will be the next frontier of Lp(a) trials.

查看原文本刊更多论文

近期脂蛋白(a)试验。

综述目的:脂蛋白(a) (Lp(a))是心血管疾病和钙化主动脉狭窄的遗传决定的独立危险因素;因此，高胆固醇血症和高甘油三酯血症的常规治疗对血清水平的影响最小。新的直接靶向Lp(a)的RNA疗法已证明在降低血清水平方面有效。最近的几项试验已经证明了这些RNA疗法的有效性和安全性。最近发现:单链反义寡核苷酸(ASOs)和小干扰RNA (siRNA)是两类RNA靶向治疗药物，它们特异性靶向LPA基因，该基因编码载脂蛋白(a)，载脂蛋白(a)是肝脏合成Lp(a)颗粒的主要和限速成分。Pelacarsen (ASO)、olpasiran (siRNA)和SLN360 (siRNA)是具有降低Lp(a)水平疗效和良好安全性的新型药物。摘要:Lp(a)是心血管疾病的独立危险因素。rna导向疗法pelacarsen、olpasiran和SLN360已显示出显著降低血清Lp(a)水平的疗效。结果数据将是Lp(a)试验的下一个前沿领域。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in lipidology 医学-内分泌学与代谢

CiteScore

6.70

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.